ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2025-8-2-9-22ojrdrt-434Research ArticleЛУЧЕВАЯ ТЕРАПИЯRADIOTHERAPYПерспективная роль послеоперационной стереотаксической лучевой терапии у больных раком предстательной железы.Promising Role of Postoperative Stereotactic Radiation Therapy for Patients with Prostate Cancer.https://orcid.org/0000-0003-1873-1293НовиковР. В.NovikovR. V.

197758, Песочный пос., Санкт-Петербург, ул. Ленинградская, 68;194175 Санкт-Петербург, ул. Академика Лебедева, 6

https://orcid.org/0009-0008-6497-6404КузнецовН. О.KuznetsovN. O.

Кузнецов Никита Олегович

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

alkealol27@gmail.comhttps://orcid.org/0000-0002-7185-1967НовиковС. Н.NovikovS. N.

197758, Песочный пос., Санкт-Петербург, ул. Ленинградская, 68

Национальный медицинский исследовательский центp онкологии им. Н.Н. Петрова Минздрава России; Военно-медицинская академии имени С. М. Кирова МО РФРоссияN.N. Petrov National Medical Research Center of Oncology; S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian FederationRussian FederationПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияFirst Pavlov State Medical University of St. PetersburgRussian FederationНациональный медицинский исследовательский центp онкологии им. Н.Н. Петрова Минздрава РоссииРоссияN.N. Petrov National Medical Research Center of OncologyRussian Federation20252906202582922Copyright © Новиков Р.В., Кузнецов Н.О., Новиков С.Н., 20252025Новиков Р.В., Кузнецов Н.О., Новиков С.Н.Novikov R.V., Kuznetsov N.O., Novikov S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/434

Послеоперационная лучевая терапия — стандартная лечебная тактика у больных раком предстательной железы (РПЖ) после радикальной простатэктомии (РПЭ), показаниями к которой являются высокий риск прогрессии (адъювантная лучевая терапия), а также регистрация биохимического или клинического рецидива заболевания (спасительная лучевая терапия). В последние годы проводятся исследования по оценке эффективности и безопасности использования у больных этой категории гипофракционированных режимов облучения, существенно сокращающих сроки лечения. Начиная с 2015 г., в зарубежной практике начали применять режим экстремального гипофракционирования или стереотаксической лучевой терапии (СТЛТ) на область ложа удаленной предстательной железы (ЛУПЖ), позволяющий подвести всю предписанную дозу за пять-семь фракций. В настоящее время НМИЦ онкологии им. Н.Н. Петрова обладает длительным (более пяти лет) опытом применения СТЛТ на область ЛУПЖ. Цель данной работы — ознакомить радиационных онкологов, онкоурологов и специалистов смежных специальностей с различными аспектами нового перспективного подхода к послеоперационному облучению области ЛУПЖ.

Radiation therapy is the standard therapeutic option in patients with prostate cancer (PCa) after radical prostatectomy (RPE), the indications for which are a high risk of postoperative progression (adjuvant radiation therapy) or registration of biochemical (clinical) recurrence of the disease (salvage radiation therapy). In recent years, studies have been conducted to assess the efficacy and safety of the use of hypofractionated radiation regimens in this category of patients, which significantly reduce the duration of treatment. Starting from 2016, the regimen of extreme hypofractionation or stereotactic radiation therapy (STRT) to the prostate bed (PB) began to be used in world practice, which makes it possible to deliver the prescribed dose in five-seven fractions. Currently, the N.N. Petrov National Medical Research Center of Oncology has matured long-term (more than five years) experience in performing STRT to the PB. The purpose of this work — to inform oncourologists, radiation oncologists and specialists in related areas with various aspects of a new perspective approach to postoperative radiation to the PB.

радикальная простатэктомиябиохимический рецидивместный рецидивложе удаленной предстательной железыстереотаксическая лучевая терапияадъювантнаяспасительнаяradical prostatectomybiochemical relapselocal relapseprostate bedstereotactic radiation therapyadjuvantsalvageReferencesZaorsky NG, Calais J, Fanti S, et al. Salvage therapy for pros‑ tate cancer after radical prostatectomy. Nat Rev Urol. 2021;18(11):643-68. https://doi.org/10.1038/s41585-021-00497-7. PMID: 34363040..Moris L, Gandaglia G, Vilaseca A, et al. Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. Eur Urol Focus. 2022;8(3):690-700. https://doi.org/10.1016/j.euf.2021.05.009. PMID: 34147405.Moris L, Gandaglia G, Vilaseca A, et al. Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. Eur Urol Focus. 2022;8(3):690-700. https://doi.org/10.1016/j.euf.2021.05.009. PMID: 34147405.Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164-82. PMID: 38688773. https://doi.org/10.1016/j.eururo.2024.04.010.Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164-82. PMID: 38688773. https://doi.org/10.1016/j.eururo.2024.04.010.Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140-50. https://doi.org/10.6004/jnccn.2024.0019. PMID: 38626801.Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140-50. https://doi.org/10.6004/jnccn.2024.0019. PMID: 38626801.Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemi‑ cal Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211(4):518-25. PMID: 38421243. https://doi.org/10.1097/JU.0000000000003891Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemi‑ cal Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211(4):518-25. PMID: 38421243. https://doi.org/10.1097/JU.0000000000003891Клинические рекомендации. Рак предстательной железы 2021.https://cr.minzdrav.gov.ru.Клинические рекомендации. Рак предстательной железы 2021.https://cr.minzdrav.gov.ru.López Campos F, Sancho Pardo G, Maldonado Pijoan X, et al. Is hypofractionation acceptable for prostate bed radiotherapy. Urol Oncol. 2021;39(6):346-50. PMID: 34049781. https://doi.org/10.1016/j.urolonc.2021.02.002.López Campos F, Sancho Pardo G, Maldonado Pijoan X, et al. Is hypofractionation acceptable for prostate bed radiotherapy. Urol Oncol. 2021;39(6):346-50. PMID: 34049781. https://doi.org/10.1016/j.urolonc.2021.02.002.Corkum MT, Achard V, Morton G, et al. Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?. Clin Oncol (R Coll Radiol). 2022;34(5):340-9. https://doi.org/10.1016/j.clon.2021.12.006. PMID: 34961659.Corkum MT, Achard V, Morton G, et al. Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?. Clin Oncol (R Coll Radiol). 2022;34(5):340-9. https://doi.org/10.1016/j.clon.2021.12.006. PMID: 34961659.Malouff TD, Stross WC, Seneviratne DS, et al. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis. Prostate Cancer Prostatic Dis. 2020;23(2):349-55. https://doi.org/10.1038/s41391-019-0191-9. PMID: 31780782.Malouff TD, Stross WC, Seneviratne DS, et al. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis. Prostate Cancer Prostatic Dis. 2020;23(2):349-55. https://doi.org/10.1038/s41391-019-0191-9. PMID: 31780782.Yu JB, Sun Y, Jia AY, et al. Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. JAMA Oncol. 2023;9(12):1696-701. https://doi.org/10.1001/jamaon‑col.2023.4267. PMID: 37796479.Yu JB, Sun Y, Jia AY, et al. Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. JAMA Oncol. 2023;9(12):1696-701. https://doi.org/10.1001/jamaon‑col.2023.4267. PMID: 37796479.Schröder C, Tang H, Windisch P, et al. Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review. Cancers (Basel). 2022;14(3):696. Published 2022 Jan 29. https://doi.org/10.3390/cancers14030696. PMID: 35158961.Schröder C, Tang H, Windisch P, et al. Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review. Cancers (Basel). 2022;14(3):696. Published 2022 Jan 29. https://doi.org/10.3390/cancers14030696. PMID: 35158961.Le Guevelou J, Magne N, Counago F, et al. Stereotactic body radiation therapy after radical prostatectomy: current status and future directions. World J Urol. 2023;41(11):3333-44. https://doi.org/10.1007/s00345-023-04605-7. PMID: 37725131.Le Guevelou J, Magne N, Counago F, et al. Stereotactic body radiation therapy after radical prostatectomy: current status and future directions. World J Urol. 2023;41(11):3333-44. https://doi.org/10.1007/s00345-023-04605-7. PMID: 37725131.Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422-31. https://doi.org/10.1016/S0140-6736(20)31952-8. PMID: 33002431.Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422-31. https://doi.org/10.1016/S0140-6736(20)31952-8. PMID: 33002431.Latorzeff I, Le Guevelou J, Sargos P. Radiation therapy post radical prostatectomy: who, when and why?. Curr Opin Support Palliat Care. 2023;17(1):47-54. https://doi.org/10.1097/SPC.0000000000000627. PMID: 36367534.Latorzeff I, Le Guevelou J, Sargos P. Radiation therapy post radical prostatectomy: who, when and why?. Curr Opin Support Palliat Care. 2023;17(1):47-54. https://doi.org/10.1097/SPC.0000000000000627. PMID: 36367534.Detti B, Bonomo P, Masi L, et al. CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. World J Urol. 2016;34(3):311-7. https://doi.org/10.1007/s00345-015-1613-5. PMID: 26062525.Detti B, Bonomo P, Masi L, et al. CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. World J Urol. 2016;34(3):311-7. https://doi.org/10.1007/s00345-015-1613-5. PMID: 26062525.Ballas LK, Luo C, Chung E, et al. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019;104(1):50-60. https://doi.org/10.1016/j.ijrobp.2018.12.047. PMID: 30605751.Ballas LK, Luo C, Chung E, et al. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019;104(1):50-60. https://doi.org/10.1016/j.ijrobp.2018.12.047. PMID: 30605751.Новиков РВ, Мельник ЮС, Пономарева ОИ, и др. Первый отечественный опыт стереотаксической лучевой терапии на область ложа удаленной предстательной железы. Урологические ведомости. 2020;10(20):133-42. https://doi.org/10.17816/uroved102133-142.Novikov RV, Melnik JS, Ponomareva OI, et al. (2020). First Russian experience of the stereotactic radiotherapy on the prostate bed. Urology Reports (St.-Petersburg). 2020;10(20):133–42. (In Russ.). https://doi.org/10.17816/uroved102133-142]Новиков РВ, Мельник ЮС, Пономарева ОИ, и др. Первый отечественный опыт стереотаксической лучевой терапии на область ложа удаленной предстательной железы. Урологические ведомости. 2020;10(20):133-42. https://doi.org/10.17816/uroved102133-142.Novikov RV, Melnik JS, Ponomareva OI, et al. (2020). First Russian experience of the stereotactic radiotherapy on the prostate bed. Urology Reports (St.-Petersburg). 2020;10(20):133–42. (In Russ.). https://doi.org/10.17816/uroved102133-142]Nahum AE. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2015;27(5):260-9. https://doi.org/10.1016/j.clon.2015.02.001. PMID: 25797579.Nahum AE. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2015;27(5):260-9. https://doi.org/10.1016/j.clon.2015.02.001. PMID: 25797579.Vogelius IR, Bentzen SM. Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020;107(2):299-304. https://doi.org/10.1016/j.ijrobp.2020.01.010. PMID: 31987958.Vogelius IR, Bentzen SM. Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020;107(2):299-304. https://doi.org/10.1016/j.ijrobp.2020.01.010. PMID: 31987958.Brand DH, Kirby AM, Yarnold JR, et al. How Low Can You Go? The Radiobiology of Hypofractionation. Clin Oncol (R Coll Radiol). 2022;34(5):280-7. https://doi.org/10.1016/j.clon.2022.02.009. PMID: 35260319.Brand DH, Kirby AM, Yarnold JR, et al. How Low Can You Go? The Radiobiology of Hypofractionation. Clin Oncol (R Coll Radiol). 2022;34(5):280-7. https://doi.org/10.1016/j.clon.2022.02.009. PMID: 35260319.Арсеньев АИ, Новиков СН, Канаев СВ, и др. Радиобиология высокодозной лучевой терапии: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. — СПб.: НМИЦ онкологии им. Н.Н. Петрова, 2022. — 156 с. Arsenyev AI, Novikov SN, Kanaev SV, et al. Radiobiology of High-Dose Radiation Therapy: A Textbook for Students in Higher and Continuing Professional Education St. Petersburg: N.N. Petrov National Medical Research Center of Oncology; 2022:156. (In Russ.).Арсеньев АИ, Новиков СН, Канаев СВ, и др. Радиобиология высокодозной лучевой терапии: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. — СПб.: НМИЦ онкологии им. Н.Н. Петрова, 2022. — 156 с. Arsenyev AI, Novikov SN, Kanaev SV, et al. Radiobiology of High-Dose Radiation Therapy: A Textbook for Students in Higher and Continuing Professional Education St. Petersburg: N.N. Petrov National Medical Research Center of Oncology; 2022:156. (In Russ.).Martini A, Gandaglia G, Fossati N, et al. Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. Eur Urol Oncol. 2021;4(1):42-48. https://doi.org/10.1016/j.euo.2019.03.006. PMID: 31411971.Martini A, Gandaglia G, Fossati N, et al. Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. Eur Urol Oncol. 2021;4(1):42-48. https://doi.org/10.1016/j.euo.2019.03.006. PMID: 31411971.Koskas Y, Lannes F, Branger N, et al. Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up. BMC Urol. 2019;19(1):37. Published 2019 May 15. https://doi.org/10.1186/s12894-019-0470-8. PMID: 31092240.Koskas Y, Lannes F, Branger N, et al. Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up. BMC Urol. 2019;19(1):37. Published 2019 May 15. https://doi.org/10.1186/s12894-019-0470-8. PMID: 31092240.Preisser F, Coxilha G, Heinze A, et al. Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer. Prostate. 2019;79(16):1832-6. https://doi.org/10.1002/pros.23908. PMID: 31553506.Preisser F, Coxilha G, Heinze A, et al. Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer. Prostate. 2019;79(16):1832-6. https://doi.org/10.1002/pros.23908. PMID: 31553506.Matti B, Reeves F, Prouse M, et al. The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers. Prostate. 2021;81(16):1428-34. https://doi.org/10.1002/pros.24240. PMID: 34570379.Matti B, Reeves F, Prouse M, et al. The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers. Prostate. 2021;81(16):1428-34. https://doi.org/10.1002/pros.24240. PMID: 34570379.Kimura S, Urabe F, Sasaki H, et al. Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021;13(5):948. Published 2021 Feb 24. https://doi.org/10.3390/cancers13050948. PMID: 33668270.Kimura S, Urabe F, Sasaki H, et al. Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021;13(5):948. Published 2021 Feb 24. https://doi.org/10.3390/cancers13050948. PMID: 33668270.Tilki D, Preisser F, Graefen M. et al. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. Eur Urol. 2019;75(6):896-900. https://doi.org/10.1016/j.eururo.2019.03.016. PMID: 30955970.Tilki D, Preisser F, Graefen M. et al. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. Eur Urol. 2019;75(6):896-900. https://doi.org/10.1016/j.eururo.2019.03.016. PMID: 30955970.Koerber SA, Höcht S, Aebersold D, et al. Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2024;200(3):181-7. https://doi.org/10.1007/s00066-023-02193–4. PMID: 38273135.Koerber SA, Höcht S, Aebersold D, et al. Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2024;200(3):181-7. https://doi.org/10.1007/s00066-023-02193–4. PMID: 38273135.Le Roy C, Gassa F, Rouvière O, et al. Salvage low-doserate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review. Brachytherapy. 2021;20(1):19-28. https://doi.org/10.1016/j.brachy.2020.07.001. PMID: 32798180.Le Roy C, Gassa F, Rouvière O, et al. Salvage low-doserate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review. Brachytherapy. 2021;20(1):19-28. https://doi.org/10.1016/j.brachy.2020.07.001. PMID: 32798180.Aghili M, Jafari F, Yamrali M, et al. Safety and efficacy of salvage high-dose rate brachytherapy for prostate-bed recurrences following radical prostatectomy and external beam radiotherapy. Int Urol Nephrol. 2022;54(5):1031-7. https://doi.org/10.1007/s11255-022-03155-y. PMID: 35239137.Aghili M, Jafari F, Yamrali M, et al. Safety and efficacy of salvage high-dose rate brachytherapy for prostate-bed recurrences following radical prostatectomy and external beam radiotherapy. Int Urol Nephrol. 2022;54(5):1031-7. https://doi.org/10.1007/s11255-022-03155-y. PMID: 35239137.Browne BM, Vanni AJ. Management of Urethral Stricture and Bladder Neck Contracture Following Primary and Salvage Treatment of Prostate Cancer. Curr Urol Rep. 2017;18(10):76. https://doi.org/10.1007/s11934-017-0729-0. PMID: 28776126.Browne BM, Vanni AJ. Management of Urethral Stricture and Bladder Neck Contracture Following Primary and Salvage Treatment of Prostate Cancer. Curr Urol Rep. 2017;18(10):76. https://doi.org/10.1007/s11934-017-0729-0. PMID: 28776126.Uguzova S, Beisland C, Honoré A, et al. Refractory Bladder Neck Contracture (BNC) After Radical Prostatectomy: Prevalence, Impact and Management Challenges. Res Rep Urol. 2023;15:495-507. Published 2023 Nov 7. https://doi.org/10.2147/RRU.S350777. PMID: 37954870.Uguzova S, Beisland C, Honoré A, et al. Refractory Bladder Neck Contracture (BNC) After Radical Prostatectomy: Prevalence, Impact and Management Challenges. Res Rep Urol. 2023;15:495-507. Published 2023 Nov 7. https://doi.org/10.2147/RRU.S350777. PMID: 37954870.Kan KM, Tin AL, Stearns GL, et al. De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors. J Urol. 2022;207(3):601-8. https://doi.org/10.1097/JU.0000000000002312. PMID: 34694923.Kan KM, Tin AL, Stearns GL, et al. De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors. J Urol. 2022;207(3):601-8. https://doi.org/10.1097/JU.0000000000002312. PMID: 34694923.Kitamura H, Tsukamoto T. Rectourinary fistula after radical prostatectomy: review of the literature for incidence, etiology, and management. Prostate Cancer. 2011;2011:629105. https://doi.org/10.1155/2011/629105. PMID: 22110993.Kitamura H, Tsukamoto T. Rectourinary fistula after radical prostatectomy: review of the literature for incidence, etiology, and management. Prostate Cancer. 2011;2011:629105. https://doi.org/10.1155/2011/629105. PMID: 22110993.Wiltshire KL, Brock KK, Haider MA, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;69(4):1090-9. https://doi.org/10.1016/j.ijrobp.2007.04.068. PMID: 17967303.Wiltshire KL, Brock KK, Haider MA, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;69(4):1090-9. https://doi.org/10.1016/j.ijrobp.2007.04.068. PMID: 17967303.Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84(2):121-7. https://doi.org/10.1016/j.radonc.2007.07.017. PMID: 17706307.Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84(2):121-7. https://doi.org/10.1016/j.radonc.2007.07.017. PMID: 17706307.Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol. 2008;88(1):10-9. https://doi.org/10.1016/j.radonc.2008.05.006. PMID: 18514340.Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol. 2008;88(1):10-9. https://doi.org/10.1016/j.radonc.2008.05.006. PMID: 18514340.Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361 8. https://doi.org/10.1016/j.ijrobp.2009.02.006. PMID: 19394158.Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361 8. https://doi.org/10.1016/j.ijrobp.2009.02.006. PMID: 19394158.Latorzeff I, Sargos P, Loos G, et al. Delineation of the Prostate Bed: The “Invisible Target” Is Still an Issue?. Front Oncol. 2017;7:108. Published 2017 May 31. https://doi.org/10.3389/fonc.2017.00108. PMID: 28620579.Latorzeff I, Sargos P, Loos G, et al. Delineation of the Prostate Bed: The “Invisible Target” Is Still an Issue?. Front Oncol. 2017;7:108. Published 2017 May 31. https://doi.org/10.3389/fonc.2017.00108. PMID: 28620579.Robin S, Jolicoeur M, Palumbo S, et al. Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021;109(5):1243-53. https://doi.org/10.1016/j.ijrobp.2020.11.010. PMID: 33186618.Robin S, Jolicoeur M, Palumbo S, et al. Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021;109(5):1243-53. https://doi.org/10.1016/j.ijrobp.2020.11.010. PMID: 33186618.Dal Pra A, Dirix P, Khoo V, et al. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. Clin Transl Radiat Oncol. 2023;41:100638. Published 2023 May 9. https://doi.org/10.1016/j.ctro.2023.100638. PMID: 37251620.Dal Pra A, Dirix P, Khoo V, et al. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. Clin Transl Radiat Oncol. 2023;41:100638. Published 2023 May 9. https://doi.org/10.1016/j.ctro.2023.100638. PMID: 37251620.Sampath S, Frankel P, Vecchio BD, et al. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial. Int J Radiat Oncol Biol Phys. 2020;106(3):537-45. https://doi.org/10.1016/j.ijrobp.2019.11.005. PMID: 31733323.Sampath S, Frankel P, Vecchio BD, et al. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial. Int J Radiat Oncol Biol Phys. 2020;106(3):537-45. https://doi.org/10.1016/j.ijrobp.2019.11.005. PMID: 31733323.Jackson WC, Silva J, Hartman HE, et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019;104(4):778-89. https://doi.org/10.1016/j.ijrobp.2019.03.051. PMID: 30959121.Jackson WC, Silva J, Hartman HE, et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019;104(4):778-89. https://doi.org/10.1016/j.ijrobp.2019.03.051. PMID: 30959121.Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):889-97. https://doi.org/10.1016/j.ijrobp.2010.11.031. PMID: 21277113.Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):889-97. https://doi.org/10.1016/j.ijrobp.2010.11.031. PMID: 21277113.Olivier J, Basson L, Puech P, et al. Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results. Front Oncol. 2019;9:71. Published 2019 Feb 15. https://doi.org/10.3389/fonc.2019.00071. PMID: 30828565.Olivier J, Basson L, Puech P, et al. Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results. Front Oncol. 2019;9:71. Published 2019 Feb 15. https://doi.org/10.3389/fonc.2019.00071. PMID: 30828565.Janoray G, Reynaud-Bougnoux A, Ruffier-Loubière A, et al. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report. Cancer Radiother. 2016;20(4):275-81. https://doi.org/10.1016/j.canrad.2016.03.005. PMID: 27342944.Janoray G, Reynaud-Bougnoux A, Ruffier-Loubière A, et al. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report. Cancer Radiother. 2016;20(4):275-81. https://doi.org/10.1016/j.canrad.2016.03.005. PMID: 27342944.Francolini G, Jereczek-Fossa BA, Di Cataldo V, et al. Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis. Radiol Med. 2022;127(4):449-57. https://doi.org/10.1007/s11547-022-01465-w. PMID: 35247134.Francolini G, Jereczek-Fossa BA, Di Cataldo V, et al. Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis. Radiol Med. 2022;127(4):449-57. https://doi.org/10.1007/s11547-022-01465-w. PMID: 35247134.Santamaria R, Zaffaroni M, Vincini MG, et al. Image-Guided Stereotactic Body Radiotherapy on Detectable Prostate Bed Recurrence after Prostatectomy in RT-Naïve Patients. Life (Basel). 2024;14(7):870. Published 2024 Jul 11. https://doi.org/10.3390/life14070870. PMID: 39063623.Santamaria R, Zaffaroni M, Vincini MG, et al. Image-Guided Stereotactic Body Radiotherapy on Detectable Prostate Bed Recurrence after Prostatectomy in RT-Naïve Patients. Life (Basel). 2024;14(7):870. Published 2024 Jul 11. https://doi.org/10.3390/life14070870. PMID: 39063623.Lucchini R, Franzese C, Vukcaj S, et al. Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial. Curr Oncol. 2022;29(12):9349-56. Published 2022 Nov 30. https://doi.org/10.3390/curroncol29120733. PMID: 36547147.Lucchini R, Franzese C, Vukcaj S, et al. Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial. Curr Oncol. 2022;29(12):9349-56. Published 2022 Nov 30. https://doi.org/10.3390/curroncol29120733. PMID: 36547147.Ferrario F, Franzese C, Faccenda V, et al. Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study. Clin Transl Radiat Oncol. 2023;44:100704. Published 2023 Nov 25. https://doi.org/10.1016/j.ctro.2023.100704. PMID: 38111610.Ferrario F, Franzese C, Faccenda V, et al. Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study. Clin Transl Radiat Oncol. 2023;44:100704. Published 2023 Nov 25. https://doi.org/10.1016/j.ctro.2023.100704. PMID: 38111610.Pinkawa M, Schubert C, Escobar-Corral N, et al. Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer. Strahlenther Onkol. 2015;191(4):375-9. https://doi.org/10.1007/s00066-014-0769-z. PMID: 25339311.Pinkawa M, Schubert C, Escobar-Corral N, et al. Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer. Strahlenther Onkol. 2015;191(4):375-9. https://doi.org/10.1007/s00066-014-0769-z. PMID: 25339311.Hong A, Bolton D, Pham T, et al. Rectal Spacer Reduces Gastrointestinal Side Effects of Radiation Post Radical Prostatectomy. Société Internationale d’Urologie Journal. 2024;5(2). https://doi.org/10.3390/siuj502002.Hong A, Bolton D, Pham T, et al. Rectal Spacer Reduces Gastrointestinal Side Effects of Radiation Post Radical Prostatectomy. Société Internationale d’Urologie Journal. 2024;5(2). https://doi.org/10.3390/siuj502002.Новиков РВ, Живулина ТВ, Сысоева ВВ, и др. Методологические аспекты имплантации отечественного парапростатического спейсера на основе стабилизированной гиалуроновой кислоты неживотного происхождения. Онкоурология 2024;20(1):67-78. https://doi.org/10.17650/1726-9776-2024-20-1-67-78.Новиков РВ, Живулина ТВ, Сысоева ВВ, и др. Методологические аспекты имплантации отечественного парапростатического спейсера на основе стабилизированной гиалуроновой кислоты неживотного происхождения. Онкоурология 2024;20(1):67-78. https://doi.org/10.17650/1726-9776-2024-20-1-67-78.

The authors declare that there are no conflicts of interest present.